Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 80 | 116 | 65 | 64 | 7 |
| Gross Profit | 80 | 116 | 65 | 64 | 7 |
| Operating Expenses | 4,848 | 6,319 | 4,780 | 4,399 | 4,520 |
| Operating Income | -4,769 | -6,202 | -4,715 | -4,335 | -4,513 |
| Interest Expense | 0 | 0 | 0 | 0 | -19 |
| Other Income | 174 | 424 | 237 | 56 | 0 |
| Pre-tax Income | -4,595 | -5,778 | -4,478 | -4,279 | -4,495 |
| Net Income Continuous | -4,595 | -5,778 | -4,478 | -4,279 | -4,495 |
| Net Income | $-4,595 | $-5,778 | $-4,478 | $-4,279 | $-4,495 |
| EPS Basic Total Ops | -0.75 | -0.94 | -0.98 | -1.04 | -1.06 |
| EPS Basic Continuous Ops | -0.75 | -0.94 | -0.98 | -1.01 | -1.06 |
| EPS Diluted Total Ops | -0.75 | -0.94 | -0.98 | -1.04 | -1.06 |
| EPS Diluted Continuous Ops | -0.75 | -0.94 | -0.98 | -1.01 | -1.06 |
| EBITDA(a) | $-4,762 | $-6,043 | $-4,710 | $-4,330 | $-4,513 |